þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________ TO _____________
|
|
NU SKIN ENTERPRISES, INC.
|
|
||
|
(Exact name of registrant as specified in its charter)
|
|
||
Delaware
|
|
|
|
87-0565309
|
(State or other jurisdiction of incorporation or organization)
|
75 WEST CENTER STREET
PROVO UT 84601
|
(IRS Employer Identification No.)
|
||
|
(Address of principal executive offices, including zip code)
|
|
||
|
(801) 345-1000
|
|
||
|
(Registrant's telephone number, including area code)
|
|
Large accelerated filer þ
|
Accelerated filer ¨
|
|
|
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
|
Smaller reporting company ¨
|
|
|
|
|
Page
|
Part I.
|
Financial Information
|
|
|
|
|
Item 1.
|
Financial Statements (Unaudited):
|
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
Item 2.
|
|
12
|
|
|
Item 3.
|
|
25
|
|
|
Item 4.
|
|
25
|
|
|
|
|
|
|
|
|
|
|
|
Part II.
|
Other Information
|
|
|
|
|
Item 1.
|
|
26
|
|
|
Item 1A.
|
|
26
|
|
|
Item 2.
|
|
27
|
|
|
Item 3.
|
|
27
|
|
|
Item 4.
|
|
27
|
|
|
Item 5.
|
|
27
|
|
|
Item 6.
|
|
29
|
|
|
|
|
|
|
|
|
|
31
|
|
June 30,
|
December 31,
|
||||||
|
2012
|
2011
|
||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
371,801
|
$
|
272,974
|
||||
Current investments
|
13,639
|
17,727
|
||||||
Accounts receivable
|
44,198
|
31,615
|
||||||
Inventories, net
|
124,677
|
112,111
|
||||||
Prepaid expenses and other
|
90,525
|
95,660
|
||||||
|
644,840
|
530,087
|
||||||
|
||||||||
Property and equipment, net
|
169,527
|
149,505
|
||||||
Goodwill
|
112,446
|
112,446
|
||||||
Other intangible assets, net
|
79,094
|
83,333
|
||||||
Other assets
|
129,064
|
115,585
|
||||||
Total assets
|
$
|
1,134,971
|
$
|
990,956
|
||||
|
||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
44,764
|
$
|
32,181
|
||||
Accrued expenses
|
226,213
|
180,382
|
||||||
Current portion of long-term debt
|
28,100
|
28,608
|
||||||
|
299,077
|
241,171
|
||||||
|
||||||||
Long-term debt
|
190,712
|
107,944
|
||||||
Other liabilities
|
77,913
|
67,605
|
||||||
Total liabilities
|
567,702
|
416,720
|
||||||
|
||||||||
Commitments and contingencies (Note 9)
|
||||||||
|
||||||||
Stockholders' equity:
|
||||||||
Class A common stock - 500 million shares authorized, $.001 par value, 90.6 million shares issued
|
91
|
91
|
||||||
Additional paid-in capital
|
305,336
|
292,240
|
||||||
Treasury stock, at cost - 30.4 million and 28.3 million shares
|
(629,078
|
)
|
(522,162
|
)
|
||||
Retained earnings
|
950,127
|
866,632
|
||||||
Accumulated other comprehensive loss
|
(59,207
|
)
|
(62,565
|
)
|
||||
|
567,269
|
574,236
|
||||||
Total liabilities and stockholders' equity
|
$
|
1,134,971
|
$
|
990,956
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||
|
2012
|
2011
|
2012
|
2011
|
||||||||||||
|
||||||||||||||||
Revenue
|
$
|
593,235
|
$
|
424,426
|
$
|
1,055,237
|
$
|
820,271
|
||||||||
Cost of sales
|
95,584
|
71,168
|
171,340
|
171,822
|
(1)
|
|||||||||||
|
||||||||||||||||
Gross profit
|
497,651
|
353,258
|
883,897
|
648,449
|
||||||||||||
|
||||||||||||||||
Operating expenses:
|
||||||||||||||||
Selling expenses
|
267,363
|
183,500
|
469,898
|
352,642
|
||||||||||||
General and administrative expenses
|
132,376
|
103,712
|
244,424
|
204,854
|
||||||||||||
|
||||||||||||||||
Total operating expenses
|
399,739
|
287,212
|
714,322
|
557,496
|
||||||||||||
|
||||||||||||||||
Operating income
|
97,912
|
66,046
|
169,575
|
90,953
|
||||||||||||
Other income (expense), net
|
(3,369
|
)
|
(127
|
)
|
266
|
(549
|
)
|
|||||||||
|
||||||||||||||||
Income before provision for income taxes
|
94,543
|
65,919
|
169,841
|
90,404
|
||||||||||||
Provision for income taxes
|
34,136
|
24,218
|
61,605
|
33,395
|
||||||||||||
|
||||||||||||||||
Net income
|
$
|
60,407
|
$
|
41,701
|
$
|
108,236
|
$
|
57,009
|
||||||||
|
||||||||||||||||
Net income per share (Note 2):
|
||||||||||||||||
Basic
|
$
|
0.98
|
$
|
0.67
|
$
|
1.75
|
$
|
0.92
|
||||||||
Diluted
|
$
|
0.94
|
$
|
0.65
|
$
|
1.67
|
$
|
0.89
|
||||||||
|
||||||||||||||||
Weighted-average common shares outstanding (000s):
|
||||||||||||||||
Basic
|
61,706
|
61,806
|
62,016
|
61,817
|
||||||||||||
Diluted
|
64,230
|
64,193
|
64,773
|
64,177
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||
|
2012
|
2011
|
2012
|
2011
|
||||||||||||
|
||||||||||||||||
Net income
|
$
|
60,407
|
$
|
41,701
|
$
|
108,236
|
$
|
57,009
|
||||||||
|
||||||||||||||||
Other comprehensive income, net of tax:
|
||||||||||||||||
Foreign currency translation adjustment
|
(3,108
|
)
|
2,129
|
1,268
|
4,537
|
|||||||||||
Net unrealized gains/(losses) on foreign currency cash flow hedges
|
(1,461
|
)
|
(826
|
)
|
1,960
|
145
|
||||||||||
Less: Reclassification adjustment for realized losses (gains) in current earnings
|
(87
|
)
|
(93
|
)
|
130
|
(104
|
)
|
|||||||||
|
(4,656
|
)
|
1,210
|
3,358
|
4,578
|
|||||||||||
|
||||||||||||||||
Comprehensive income
|
$
|
55,751
|
$
|
42,911
|
$
|
111,594
|
$
|
61,587
|
|
Six Months Ended
|
|||||||
|
June 30,
|
|||||||
|
2012
|
2011
|
||||||
Cash flows from operating activities:
|
||||||||
Net income
|
$
|
108,236
|
$
|
57,009
|
||||
Adjustments to reconcile net income to net cash
|
||||||||
provided by operating activities: | ||||||||
Depreciation and amortization
|
16,938
|
15,853
|
||||||
Japan customs expense
|
−
|
32,754
|
||||||
Foreign currency (gains)/losses
|
(938
|
)
|
(1,763
|
)
|
||||
Stock-based compensation
|
11,131
|
7,762
|
||||||
Deferred taxes
|
3,508
|
(7,580
|
)
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(13,447
|
)
|
(6,423
|
)
|
||||
Inventories, net
|
(12,912
|
)
|
7,943
|
|||||
Prepaid expenses and other
|
(7,441
|
)
|
(1,882
|
)
|
||||
Other assets
|
(12,479
|
)
|
(13,152
|
)
|
||||
Accounts payable
|
12,152
|
2,372
|
||||||
Accrued expenses
|
56,860
|
(23,571
|
)
|
|||||
Other liabilities
|
6,746
|
11,466
|
||||||
|
||||||||
Net cash provided by operating activities
|
168,354
|
80,788
|
||||||
|
||||||||
Cash flows from investing activities:
|
||||||||
Purchases of property and equipment
|
(30,142
|
)
|
(16,440
|
)
|
||||
Proceeds of investment sales
|
13,944
|
−
|
||||||
Purchases of investments
|
(9,855
|
)
|
−
|
|||||
|
||||||||
Net cash used in investing activities
|
(26,053
|
)
|
(16,440
|
)
|
||||
|
||||||||
Cash flows from financing activities:
|
||||||||
Exercise of employee stock options
|
1,951
|
13,039
|
||||||
Payment of debt
|
(15,398
|
)
|
(15,058
|
)
|
||||
Payment of cash dividends
|
(24,741
|
)
|
(16,714
|
)
|
||||
Income tax benefit of options exercised
|
6,316
|
4,747
|
||||||
Proceeds from long term debt
|
100,006
|
−
|
||||||
Payment of related party debt
|
−
|
(16,995
|
)
|
|||||
Repurchases of shares of common stock
|
(113,314
|
)
|
(33,817
|
)
|
||||
|
||||||||
Net cash used in financing activities
|
(45,180
|
)
|
(64,798
|
)
|
||||
|
||||||||
Effect of exchange rate changes on cash
|
1,706
|
3,516
|
||||||
|
||||||||
Net increase in cash and cash equivalents
|
98,827
|
3,066
|
||||||
|
||||||||
Cash and cash equivalents, beginning of period
|
272,974
|
230,337
|
||||||
|
||||||||
Cash and cash equivalents, end of period
|
$
|
371,801
|
$
|
233,403
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||
Revenue:
|
2012
|
2011
|
2012
|
2011
|
||||||||||||
|
||||||||||||||||
North Asia
|
$
|
177,695
|
$
|
183,097
|
$
|
359,895
|
$
|
362,531
|
||||||||
Greater China
|
199,728
|
79,404
|
292,339
|
147,997
|
||||||||||||
South Asia/Pacific
|
98,344
|
59,212
|
175,665
|
109,158
|
||||||||||||
Americas
|
71,766
|
59,805
|
138,106
|
115,684
|
||||||||||||
Europe (region)
|
45,702
|
42,908
|
89,232
|
84,901
|
||||||||||||
Totals
|
$
|
593,235
|
$
|
424,426
|
$
|
1,055,237
|
$
|
820,271
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||
Revenue:
|
2012
|
2011
|
2012
|
2011
|
||||||||||||
|
||||||||||||||||
Nu Skin
|
$
|
295,068
|
$
|
227,931
|
$
|
544,583
|
$
|
444,891
|
||||||||
Pharmanex
|
296,292
|
194,104
|
506,597
|
370,301
|
||||||||||||
Other
|
1,875
|
2,391
|
4,057
|
5,079
|
||||||||||||
Totals
|
$
|
593,235
|
$
|
424,426
|
$
|
1,055,237
|
$
|
820,271
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||
Revenue:
|
2012
|
2011
|
2012
|
2011
|
||||||||||||
|
||||||||||||||||
Japan
|
$
|
115,615
|
$
|
115,067
|
$
|
225,679
|
$
|
226,900
|
||||||||
Hong Kong
|
101,928
|
12,295
|
118,789
|
24,620
|
||||||||||||
South Korea
|
62,080
|
68,030
|
134,216
|
135,631
|
||||||||||||
United States
|
57,485
|
49,621
|
111,401
|
96,851
|
||||||||||||
Mainland China
|
57,299
|
38,110
|
108,137
|
69,166
|
||||||||||||
Taiwan
|
40,501
|
28,999
|
65,413
|
54,211
|
||||||||||||
Europe
|
40,100
|
37,126
|
77,842
|
72,757
|
Long-lived assets:
|
June 30, 2012
|
December 31, 2011
|
||||||
|
||||||||
Japan
|
$
|
9,455
|
$
|
14,113
|
||||
Hong Kong
|
782
|
1,030
|
||||||
South Korea
|
11,706
|
11,451
|
||||||
United States
|
124,020
|
98,205
|
||||||
Mainland China
|
10,796
|
15,135
|
||||||
Taiwan
|
1,549
|
1,556
|
||||||
Europe
|
2,049
|
1,966
|
Facility or Arrangement(1)
|
|
Original Principal Amount
|
|
Balance as of
December 31, 2011
|
|
Balance as of
June 30, 2012(2)
|
|
Interest Rate
|
|
Repayment terms
|
Multi-currency uncommitted shelf facility:
|
|
|
|
|
|
|
|
|
|
|
U.S. dollar denominated:
|
|
$40.0 million
|
|
$28.6 million
|
|
$28.6 million
|
|
6.2%
|
|
Notes due July 2016 with annual principal payments that began in July 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$20.0 million
|
|
$17.1 million
|
|
$14.3 million
|
|
6.2%
|
|
Notes due January 2017 with annual principal payments that began in January 2011.
|
|
|
|
|
|
|
|
|
|
|
|
Japanese yen denominated:
|
|
3.1 billion yen
|
|
1.3 billion yen ($17.4 million as of December 31, 2011)
|
|
0.9 billion yen ($11.2 million as of June 30, 2012)
|
|
1.7%
|
|
Notes due April 2014 with annual principal payments that began in April 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.3 billion yen
|
|
1.9 billion yen ($25.3 million as of December 31, 2011)
|
|
1.9 billion yen ($24.3 million as of June 30, 2012)
|
|
2.6%
|
|
Notes due September 2017 with annual principal payments that began in September 2011.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.2 billion yen
|
|
1.9 billion yen ($24.2 million as of December 31, 2011)
|
|
1.5 billion yen ($19.4 million as of June 30, 2012)
|
|
3.3%
|
|
Notes due January 2017 with annual principal payments that began in January 2011.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.0 billion yen(3)
|
|
N/A
|
|
8.0 billion yen ($100.0 million as of June 30, 2012)
|
|
1.7%
|
|
Notes due May 2022 with annual principal payments that begin in May 2016.
|
|
|
|
|
|
|
|
|
|
|
|
Committed loan:
|
|
|
|
|
|
|
|
|
|
|
U.S. dollar denominated:
|
|
$30.0 million
|
|
$24.0 million
|
|
$21.0 million
|
|
Variable 30 day: 1.24%
|
|
Amortizes at $1.5 million per quarter.
|
|
|
|
|
|
|
|
|
|
|
|
Revolving credit facility
|
|
N/A
|
|
None
|
|
None
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||||||||||
|
2012
|
2011
|
Change
|
2012
|
2011
|
Change
|
||||||||||||||||||
|
||||||||||||||||||||||||
Japan
|
$
|
115.6
|
$
|
115.1
|
*
|
$
|
225.7
|
$
|
226.9
|
(1%)
|
|
|||||||||||||
South Korea
|
62.1
|
68.0
|
(9%)
|
|
134.2
|
135.6
|
(1%)
|
|||||||||||||||||
North Asia total
|
$
|
177.7
|
$
|
183.1
|
(3$)
|
|
$
|
359.9
|
$
|
362.5
|
(1%)
|
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||||||||||
|
2012
|
2011
|
Change
|
2012
|
2011
|
Change
|
||||||||||||||||||
|
||||||||||||||||||||||||
Hong Kong
|
$
|
101.9
|
$
|
12.3
|
728%
|
|
$
|
118.8
|
$
|
24.6
|
383%
|
|
||||||||||||
Mainland China
|
57.3
|
38.1
|
50%
|
|
108.1
|
69.2
|
56%
|
|
||||||||||||||||
Taiwan
|
40.5
|
29.0
|
40%
|
|
65.4
|
54.2
|
21%
|
|
||||||||||||||||
Greater China total
|
$
|
199.7
|
$
|
79.4
|
152%
|
|
$
|
292.3
|
$
|
148.0
|
98%
|
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||||||||||
|
2012
|
2011
|
Change
|
2012
|
2011
|
Change
|
||||||||||||||||||
|
||||||||||||||||||||||||
South Asia/Pacific
|
$
|
98.3
|
$
|
59.2
|
66%
|
|
$
|
175.7
|
$
|
109.2
|
61%
|
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||||||||||
|
2012
|
2011
|
Change
|
2012
|
2011
|
Change
|
||||||||||||||||||
|
||||||||||||||||||||||||
Americas
|
$
|
71.8
|
$
|
59.8
|
20%
|
|
$
|
138.1
|
$
|
115.7
|
19%
|
|
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||||||||||
|
June 30,
|
June 30,
|
||||||||||||||||||||||
|
2012
|
2011
|
Change
|
2012
|
2011
|
Change
|
||||||||||||||||||
|
||||||||||||||||||||||||
Europe
|
$
|
45.7
|
$
|
42.9
|
7%
|
|
$
|
89.2
|
$
|
84.9
|
5%
|
|
• | planning and construction of a new innovation center on our Provo campus and a new Greater China regional headquarters in Shanghai, China, and related real estate acquisitions; |
• | the build-out and upgrade of leasehold improvements in our various markets, including retail stores in China; and |
• | purchases of computer systems and software, including equipment and development costs. |
Facility or Arrangement(1)
|
|
Original Principal Amount
|
|
Balance as of
June 30, 2012(2)
|
|
Interest Rate
|
|
Repayment terms
|
|
Multi-currency uncommitted shelf facility:
|
|
|
|
|
|
|
|
|
|
U.S. dollar denominated:
|
|
$40.0 million
|
|
$28.6 million
|
|
6.2%
|
|
Notes due July 2016 with annual principal payments that began in July 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$20.0 million
|
|
$14.3 million
|
|
6.2%
|
|
Notes due January 2017 with annual principal payments that began in January 2011.
|
|
|
|
|
|
|
|
|
|
|
|
Japanese yen denominated:
|
|
3.1 billion yen
|
|
0.9 billion yen ($11.2 million as of June 30, 2012)
|
|
1.7%
|
|
Notes due April 2014 with annual principal payments that began in April 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.3 billion yen
|
|
1.9 billion yen ($24.3 million as of June 30, 2012)
|
|
2.6%
|
|
Notes due September 2017 with annual principal payments that began in September 2011.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.2 billion yen
|
|
1.5 billion yen ($19.4 million as of June 30, 2012)
|
|
3.3%
|
|
Notes due January 2017 with annual principal payments that began in January 2011.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.0 billion yen(3)
|
|
8.0 billion yen ($100.0 million as of June 30, 2012)
|
|
1.7%
|
|
Notes due May 2022 with annual principal payments that begin in May 2016.
|
|
|
|
|
|
|
|
|
|
|
|
Committed loan:
|
|
|
|
|
|
|
|
|
|
U.S. dollar denominated:
|
|
$30.0 million
|
|
$21.0 million
|
|
Variable 30 day: 1.24%
|
|
Amortizes at $1.5 million per quarter.
|
|
|
|
|
|
|
|
|
|
|
|
Revolving credit facility
|
|
N/A
|
|
None
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of June 30, 2012
|
As of June 30, 2011
|
||||||||||||||
Region:
|
Active
|
Executive
|
Active
|
Executive
|
||||||||||||
|
||||||||||||||||
North Asia
|
337,000
|
14,370
|
331,000
|
15,127
|
||||||||||||
Greater China
|
170,000
|
20,182
|
130,000
|
9,580
|
||||||||||||
South Asia/Pacific
|
99,000
|
8,856
|
91,000
|
4,499
|
||||||||||||
Americas
|
170,000
|
5,994
|
165,000
|
5,185
|
||||||||||||
Europe
|
119,000
|
4,626
|
110,000
|
3,917
|
||||||||||||
Total
|
895,000
|
54,028
|
827,000
|
38,308
|
●
|
|
continued or increased levels of regulatory and media scrutiny and any regulatory actions taken by regulators, or any adoption of more restrictive regulations, in response to such scrutiny;
|
|
|
|
●
|
|
significant weakening of the Japanese yen;
|
|
|
|
●
|
|
increased regulatory constraints with respect to the claims we can make regarding the efficacy of products and tools, which could limit our ability to effectively market them;
|
|
|
|
●
|
|
risks that the initiatives we have implemented in Japan, which are patterned after successful initiatives implemented in other markets, will not have the same level of success in Japan, may not generate renewed growth or increased productivity among our distributors, and may cost more or require more time to implement than we have anticipated;
|
|
|
|
●
|
|
inappropriate activities by our distributors and any resulting regulatory actions;
|
|
|
|
●
|
|
improper practices of other direct selling companies or their distributors that increase regulatory and media scrutiny of our industry;
|
|
|
|
●
|
|
increased weakness in the economy or consumer confidence; and
|
|
|
|
●
|
|
increased competitive pressures from other direct selling companies and their distributors who actively seek to solicit our distributors to join their businesses.
|
|
Six Months Ended
June 30,
|
|||||||
|
2012
|
2011
|
||||||
|
||||||||
Revenue
|
$
|
1,055,237
|
$
|
820,271
|
||||
|
||||||||
Gross profit, as reported
|
883,897
|
648,449
|
||||||
Japan customs expense
|
−
|
32,754
|
||||||
Gross profit, excluding Japan customs expense
|
883,897
|
681,203
|
||||||
|
||||||||
Gross profit, excluding Japan customs expense, as a % of revenue
|
83.8
|
%
|
83.0
|
%
|
||||
|
||||||||
Gross profit, as reported, as a % of revenue
|
83.8
|
%
|
79.1
|
%
|
|
Six Months Ended
June 30,
|
|||||||
|
2012
|
2011
|
||||||
|
||||||||
Net income, as reported
|
$
|
108,236
|
$
|
57,009
|
||||
Japan customs expense
|
−
|
32,754
|
||||||
Tax effect of Japan customs expense
|
−
|
(12,099
|
)
|
|||||
Net income, excluding Japan customs expense
|
$
|
108,236
|
$
|
77,664
|
||||
|
||||||||
Diluted earnings per share, excluding Japan customs expense
|
$
|
1.67
|
$
|
1.21
|
||||
|
||||||||
Diluted earnings per share, as reported
|
$
|
1.67
|
$
|
0.89
|
|
(a)
|
(b)
|
(c)
|
(d)
|
||||||||||||
Period
|
Total Number of Shares Purchased
|
Average Price Paid per Share
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
(in millions)(1)
|
||||||||||||
|
||||||||||||||||
April 1 - 30, 2012
|
161,351
|
$
|
57.09
|
161,300
|
$
|
319.3
|
||||||||||
May 1 - 31, 2012
|
1,200,000
|
$
|
43.32
|
1,200,000
|
$
|
263.6
|
||||||||||
June 1 - 30, 2012
|
1,076,700
|
$
|
43.36
|
1,076,700
|
$
|
223.4
|
||||||||||
Total
|
2,438,051
|
(2)
|
2,438,000
|
(1) | In August 1998, our board of directors approved a plan to repurchase $10.0 million of our Class A common stock on the open market or in private transactions. Our board has from time to time increased the amount authorized under the plan and a total amount of approximately $735.0 million was authorized as of June 30, 2012. As of June 30, 2012, we had repurchased approximately $511.6 million of shares under the plan. On May 1, 2012, our board of directors authorized a $250.0 million extension of our ongoing share repurchase authorization which is included in the total authorized. There has been no termination or expiration of the plan since the initial date of approval. |
(2) | We have authorized the repurchase of shares acquired by our employees and distributors in certain foreign markets because of regulatory and other issues that make it difficult or costly for these persons to sell such shares in the open market. Of the shares listed in this column, 51 shares in April at an average price per share of $60.91 relate to repurchases from such employees and distributors. |
·
|
Employment Period: The executive officers' employment periods under the employment agreements will be August 1, 2012 to December 31, 2015, unless terminated earlier;
|
·
|
Compensation: The executive officers will receive base salaries, cash incentives, equity awards and other compensation, as determined by the Compensation Committee of our Board of Directors;
|
·
|
Vesting upon a Change in Control: Time-based equity awards granted to the executive officers will fully vest upon certain terminations of employment within six months prior to and in connection with, or within two years following, a change in control;
|
·
|
Termination Payments: The executive officers will receive various termination payments in specified circumstances without excise tax protection; and
|
·
|
Covenants: The executive officers will be bound by certain covenants, including non-solicitation, non-competition and non-endorsement, that are in addition to, or supersede, previous key employee covenants.
|
10.1 | Amended and Restated Credit Agreement, dated as of May 25, 2012, among the Company, various financial institutions, and JPMorgan Chase Bank, N.A. as administrative agent. |
10.2 | Amended and Restated Note Purchase and Private Shelf Agreement (Multi-Currency), dated as of May 25, 2012, among the Company, Prudential Investment Management, Inc. and certain other purchasers. |
10.3 | Series G Senior Notes Nos. G-1, G-2 and G-3, issued May 31, 2012, by the Company to The Prudential Insurance Company of America, Pruco Life Insurance Company and Prudential Retirement Insurance and Annuity Company. |
10.4 | Employment Agreement, effective as of August 1, 2012, between the Company and M. Truman Hunt. |
10.5 | Form of Employment Agreement, with schedule of material differences, effective as of August 1, 2012, between the Company and Ritch N. Wood, Daniel R. Chard, D. Matthew Dorny and Scott E. Schwerdt. |
31.1 | Certification by M. Truman Hunt, President and Chief Executive Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2 | Certification by Ritch N. Wood, Chief Financial Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1 | Certification by M. Truman Hunt, President and Chief Executive Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2 | Certification by Ritch N. Wood, Chief Financial Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema Document |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
By: /s/ Ritch N. Wood |
Its: | Chief Financial Officer |
|
|
|
SECTION 1
|
DEFINITIONS.
|
(ii)
|
In the computation of periods of time from a specified date to a later specified date, the word "from" means "from and including"; the words "to" and "until" each mean "to but excluding", and the word "through" means "to and including."
|
SECTION 2
|
COMMITMENTS OF THE LENDERS; BORROWING, CONVERSION AND LETTER OF CREDIT PROCEDURES.
|
(i)
|
elect, as of any Business Day, to convert any outstanding Floating Rate Loan into a Eurodollar Loan or any outstanding Eurodollar Loan to a Floating Rate Loan; or
|
(ii)
|
elect, as of the last day of the applicable Interest Period, to continue any Group of Yen LIBOR Loans or Eurodollar Loans having an Interest Period expiring on such day (or any part thereof in the applicable amount required for a Group pursuant to Section 2.2.1) for a new Interest Period.
|
(1)
|
the proposed date of conversion or continuation;
|
(2)
|
the aggregate amount and currency of the Loans to be converted or continued;
|
(3)
|
the Type of Loans resulting from the proposed conversion or continuation; and
|
(4)
|
in the case of continuation of Yen LIBOR Loans or conversion into, or continuation of, Eurodollar Loans, the duration of the requested Interest Period therefor.
|
SECTION 3
|
NOTES EVIDENCING LOANS.
|
SECTION 4
|
INTEREST.
|
SECTION 5
|
FEES.
|
SECTION 6
|
REDUCTION IN THE COMMITMENT AMOUNT; INCREMENTAL FACILITIES; PREPAYMENTS.
|
SECTION 7
|
MAKING AND PRORATION OF PAYMENTS; SETOFF; TAXES.
|
SECTION 8
|
INCREASED COSTS; SPECIAL PROVISIONS FOR YEN LIBOR LOANS AND EURODOLLAR LOANS.
|
(i)
|
shall subject any Lender (or any Yen LIBOR Office or Eurodollar Office of such Lender) to any tax, duty or other charge with respect to its Yen LIBOR Loans or Eurodollar Loans, its Note or its obligation to make Yen LIBOR Loans or Eurodollar Loans, or shall change the basis of taxation of payments to any Lender of the principal of or interest on its Yen LIBOR Loans or Eurodollar Loans or any other amounts due under this Agreement in respect of its Yen LIBOR Loans or Eurodollar Loans or its obligation to make Yen LIBOR Loans or Eurodollar Loans (except for changes in the rate of tax on the overall net income of such Lender or its Yen LIBOR Office or Eurodollar Office imposed by the jurisdiction in which such Lender's principal executive office, Yen LIBOR Office or Eurodollar Office is located); or
|
(ii)
|
shall impose, modify or deem applicable any reserve (including any reserve imposed by the FRB, but excluding any reserve included in the determination of interest rates pursuant to Section 4), special deposit or similar requirement against assets of, deposits with or for the account of, or credit extended by any Lender (or any Yen LIBOR Office or Eurodollar Office of such Lender); or
|
(iii)
|
shall impose on any Lender (or its Yen LIBOR Office or Eurodollar Office) any other condition affecting its Yen LIBOR Loans or Eurodollar Loans, its Note or its obligation to make Yen LIBOR Loans or Eurodollar Loans;
|
SECTION 9
|
WARRANTIES.
|
SECTION 10
|
COVENANTS.
|
(i)
|
in the case of a consolidation or merger of a Restricted Subsidiary, (x) the Company or another Restricted Subsidiary is the surviving or continuing corporation, (y) the surviving or continuing corporation is or immediately becomes a Restricted Subsidiary, or (z) such consolidation or merger, if considered as the sale of the assets of such Restricted Subsidiary to such other Person, would be permitted by Section 10.13(c); and
|
(ii)
|
in the case of a consolidation or merger of the Company, the successor corporation or surviving corporation which results from such consolidation or merger (the "surviving corporation"), if not the Company, (A) is a solvent United States corporation, (B) executes and delivers to each Lender its assumption of (x) the due and punctual payment of the principal of and premium, if any, and interest on the Loans, and (y) the due and punctual performance and observation of all of the covenants in this Agreement and each other Loan Document to be performed or observed by the Company, and (C) furnishes to each Lender an opinion of counsel, reasonably satisfactory to the Required Lenders, to the effect that the instrument of assumption has been duly authorized, executed and delivered and constitutes the legal, valid and binding contract and agreement of the surviving corporation enforceable in accordance with its terms, except as enforcement of such terms may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors' rights generally and by general equitable principles.
|
(i)
|
the successor corporation to which all or substantially all of the Company's assets have been sold, leased or transferred (the "successor corporation") is a solvent United States corporation, and
|
(ii)
|
the successor corporation executes and delivers to each Lender its assumption of the due and punctual payment of the principal of and premium, if any, and interest on the Loans, and the due and punctual performance and observation of all of the covenants in this Agreement and each other Loan Document to be performed or observed by the Company and shall furnish to the Administrative Agent an opinion of counsel, reasonably satisfactory to the Required Lenders, to the effect that the instrument of assumption has been duly authorized, executed and delivered and constitutes the legal, valid and binding contract and agreement of such successor corporation enforceable in accordance with its terms, except as enforcement of such terms may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors' rights generally and by general equitable principles.
|
(i)
|
the sale, lease, transfer or other disposition of assets of the Company to a Wholly-Owned Restricted Subsidiary or of a Restricted Subsidiary to the Company or a Wholly-Owned Restricted Subsidiary;
|
(ii)
|
the sale in the ordinary course of business of inventory held for sale, or equipment, fixtures, supplies or materials that are no longer required in the operation of the business of the Company or any Restricted Subsidiary or are obsolete;
|
(iii)
|
the sale of property of the Company or any Restricted Subsidiary and the Company's or any Restricted Subsidiary's subsequent lease, as lessee, of the same property, within 270 days following the acquisition or construction of such property;
|
(iv)
|
the sale of assets of the Company or any Restricted Subsidiary for cash or other property to a Person or Persons (other than an Affiliate) if (A) such assets (valued at net book value) do not constitute a "substantial part" (as defined below) of the assets of the Company and the Restricted Subsidiaries, (B) in the opinion of a Responsible Officer of the Company, the sale is for fair value and is in the best interests of the Company, and (C) immediately after giving effect to the transaction, no Event of Default or Unmatured Event of Default would exist; or
|
(v)
|
the sale of assets meeting the conditions set forth in clauses (B) and (C) of clause (iv) above, as long as the net proceeds from such sale in excess of a "substantial part" (as defined below) of the assets of the Company and the Restricted Subsidiaries are (x) applied within 270 days of the date of receipt to the acquisition of productive assets useful and intended to be used in the operation of the business of the Company or the Restricted Subsidiaries, or (y) used to repay any Indebtedness of the Company or the Restricted Subsidiaries (other than Indebtedness that is in any manner subordinated in right of payment or security in any respect to Indebtedness hereunder, Indebtedness owing to the Company, any of its Subsidiaries or any Affiliate and Indebtedness in respect of any revolving credit or similar credit facility providing the Company or any of the Restricted Subsidiaries with the right to obtain loans or other extensions of credit from time to time, except to the extent that in connection with such payment of Indebtedness the availability of credit under such credit facility is permanently reduced not later than 270 days after the date of receipt of such proceeds by an amount not less than the amount of such proceeds applied to the payment of such Indebtedness).
|
SECTION 11
|
CONDITIONS TO EFFECTIVENESS, ETC.
|
(i)
|
no litigation (including derivative actions), arbitration proceeding, labor controversy or governmental investigation or proceeding shall be pending or, to the knowledge of the Company, threatened against the Company or any of its Subsidiaries which might reasonably be expected to have a Material Adverse Effect or which purports to affect the legality, validity or enforceability of this Agreement, the Notes or any other Loan Document; and
|
(ii)
|
no development shall have occurred in any litigation (including derivative actions), arbitration proceeding, labor controversy or governmental investigation or proceeding disclosed pursuant to Section 9.9 which might reasonably be expected to have a Material Adverse Effect; and
|
SECTION 12
|
EVENTS OF DEFAULT AND THEIR EFFECT.
|
SECTION 13
|
THE ADMINISTRATIVE AGENT.
|
SECTION 14
|
GENERAL.
|
Number
|
Beneficiary
|
Stated Amount
|
Expiry Date
|
|
ABN AMRO Bank, NV
|
€550,000
|
4/15/2013
|
|
JPMorgan Chase Bank, N.A. London
|
£51,030.00
|
4/15/2013
|
|
Unicredit Bank Hungary, Zrt.
|
€415,000
|
4/13/2013
|
|
Level I
|
Level II
|
Level III
|
Applicable Margin for Eurodollar Loans and Yen LIBOR Loans
|
0.500%
|
0.625%
|
0.875%
|
Applicable Margin for Floating Rate Loans
|
0.000%
|
0.000%
|
0.000%
|
Fee for standby Letters of Credit
|
1.000%
|
1.250%
|
1.500%
|
Commitment Fee Rate
|
0.100%
|
0.150%
|
0.200%
|
LENDER
|
COMMITMENT
|
PERCENTAGE
|
JPMorgan Chase Bank, N.A.
|
$25,000,000
|
100.000000000%
|
Name
|
Jurisdiction
|
% Direct and Indirect Owned by Company
|
Material
|
Unrestricted
|
Big Planet, Inc.
|
Delaware
|
100%
|
|
|
First Harvest International, LLC
|
Utah
|
100%
|
|
|
Jixi Nu Skin Vitameal Co., Ltd.
|
Delaware
|
100%
|
|
|
NSE Asia Products, PTE. LTD.
|
Singapore
|
100%
|
|
|
NSE Products, Inc.
|
Delaware
|
100%
|
x
|
|
Niksun Acquisition Corporation
|
Delaware
|
100%
|
|
|
Nu Family Benefits Insurance Brokerage, Inc.
|
Utah
|
100%
|
|
|
Nu Skin (China) Daily-Use & Health Products Co., Ltd.
|
China
|
100%
|
|
|
Nu Skin (Malaysia) Sdn. Bhd.
|
Malaysia
|
50%
|
|
|
Nu Skin Argentina, Inc.
|
Utah
|
100%
|
|
x
|
Nu Skin Asia Holdings, PTE. LTD.
|
Singapore
|
100%
|
|
|
Nu Skin Asia Investment, Inc.
|
Delaware
|
100%
|
x
|
|
Nu Skin Belgium, NV
|
Belgium
|
100%
|
|
|
Nu Skin Brazil, Ltda.
|
Brazil
|
100%
|
|
|
Nu Skin Canada, Inc.
|
Utah
|
100%
|
|
|
Nu Skin Chile Enterprises Ltda.
|
Chile
|
100%
|
|
|
Nu Skin Colombia, Inc.
|
Delaware
|
100%
|
|
|
Nu Skin Costa Rica
|
Costa Rica
|
100%
|
|
|
Nu Skin Czech Republic, s.r.o.
|
Czech Republic
|
100%
|
|
|
Nu Skin Eastern Europe Ltd.
|
Hungary
|
100%
|
|
|
Nu Skin El Salvador S.A. De C.V.
|
El Salvador
|
100%
|
|
|
Nu Skin Enterprises (Thailand) Limited (Delaware Corporation)
|
Delaware
|
100%
|
|
|
Nu Skin Enterprises (Thailand) Limited (Thai Corporation)
|
Thailand
|
100%
|
|
|
Nu Skin Enterprises Australia, Inc.
|
Utah
|
100%
|
|
|
Nu Skin Enterprises Hong Kong, Inc.
|
Delaware
|
100%
|
x
|
|
Nu Skin Enterprises India Private Limited
|
India
|
100%
|
|
|
Nu Skin Enterprises New Zealand, Inc.
|
Utah
|
100%
|
|
|
Nu Skin Enterprises Philippines, Inc.
|
Delaware
|
100%
|
|
|
Nu Skin Enterprises Poland Sp. z.o.o.
|
Poland
|
100%
|
|
|
Nu Skin Enterprises RS, Ltd.
|
Rusia
|
100%
|
|
|
Nu Skin Enterprises SRL
|
Romania
|
100%
|
|
|
Nu Skin Enterprises Singapore Pte. Ltd.
|
Singapore
|
100%
|
|
|
Nu Skin Enterprises South Africa (Proprietary) Limited
|
South Africa
|
100%
|
|
|
Nu Skin Enterprises Ukraine, LLC
|
Ukraine
|
100%
|
|
x
|
Nu Skin Enterprises United States, Inc.
|
Delaware
|
100%
|
x
|
|
Nu Skin Enterprises Vietnam LLC
|
Vietnam
|
100%
|
|
|
Nu Skin France, SARL
|
France
|
100%
|
|
|
Nu Skin Germany, GmbH
|
German
|
100%
|
|
|
Nu Skin Guatemala, S.A.
|
Guatamala
|
100%
|
|
|
Nu Skin Honduras, S.A.
|
Honduras
|
100%
|
|
|
Nu Skin Hong Kong, Pte. Ltd.
|
Singapore
|
100%
|
|
|
Nu Skin International Management Group, Inc.
|
Utah
|
100%
|
|
|
Nu Skin International, Inc.
|
Utah
|
100%
|
x
|
|
Nu Skin Islandi ehf.
|
Iceland
|
100%
|
|
|
Nu Skin Israel, Inc.
|
Delaware
|
100%
|
|
x
|
Nu Skin Italy, Srl
|
Italy
|
100%
|
|
|
Nu Skin Japan Company Limited
|
Japan
|
100%
|
x
|
|
Nu Skin Japan, Ltd.
|
||||
Japan
|
100%
|
|
|
|
Nu Skin Korea Ltd.
|
Korea
|
100%
|
x
|
|
Nu Skin Malaysia Holdings Sdn. Bhd.
|
Malaysia
|
70%
|
|
|
Nu Skin Mexico, S.A. de C.V.
|
Mexico
|
100%
|
|
|
Nu Skin Netherlands, B.V.
|
Netherlands
|
100%
|
|
|
Nu Skin New Caledonia EURL
|
France
|
100%
|
|
|
Nu Skin Norway AS
|
Norway
|
100%
|
|
|
Nu Skin Pharmanex (B) Sdn. Bhd.
|
Brunei
|
100%
|
|
x
|
Nu Skin Scandinavia AS
|
Denmark
|
100%
|
|
|
Nu Skin Slovakia s.r.o.
|
Slovakia
|
100%
|
|
|
Nu Skin Taiwan, Inc.
|
Utah
|
100%
|
|
|
Nu Skin Taiwan, Inc., Taipei Branch
|
Utah
|
100%
|
|
|
Nu Skin Taiwan, Pte. Ltd.
|
Singapore
|
100%
|
|
|
Nu Skin Turkey Cilt Bakimi Ve Besleyici Urunleri Ticaret Limited Sirketi
|
Turkey
|
100%
|
|
|
Nu Skin U.K., Ltd.
|
UK
|
100%
|
|
|
Nu Skin Venezuela
|
Venezuela
|
100%
|
|
|
Nutriscan, Inc.
|
Utah
|
100%
|
|
|
PT. Nu Skin Distribution Indonesia
|
Indonesia
|
100%
|
|
|
PT. Nusa Selaras Indonesia
|
Indonesia
|
0%
|
|
|
Pharmanex (Huzhou) Health Products Co., Ltd
|
China
|
100%
|
|
|
Pharmanex Electronic-Optical Technology (Shanghai) Co. Ltd.
|
China
|
100%
|
|
|
Pharmanex License Acquisition Corporation
|
Utah
|
100%
|
|
|
Pharmanex, LLC
|
Utah
|
100%
|
|
|
The Nu Skin Force for Good Foundation
|
Utah
|
100%
|
|
|
Timpanogos Peak, LLC
|
Delaware
|
100%
|
|
|
2003 $205.0 million multi-currency uncommitted shelf facility: *
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. dollar
denominated:
|
|
$40.0 million
|
|
$28.6 million
|
|
$28.6 million
|
|
6.2%
|
|
Notes due July 2016 with annual principal payments that began in July 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$20.0 million
|
|
$17.1 million
|
|
$14.3 million
|
|
6.2%
|
|
Notes due January 2017 with annual principal payments that began in January 2011.
|
|
|
|
|
|
|
|
|
|
|
|
Japanese yen
denominated:
|
|
3.1 billion yen
|
|
1.3 billion yen ($17.4 million as of December 31, 2011)
|
|
891.4 million yen ($11.3 million as of May 21, 2012)
|
|
1.7%
|
|
Notes due April 2014 with annual principal payments that began in April 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.3 billion yen
|
|
1.9 billion yen ($25.3 million as of December 31, 2011)
|
|
1.9 billion yen ($23.9 million as of May 21, 2012)
|
|
2.6%
|
|
Notes due September 2017 with annual principal payments that began in September 2011.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.2 billion yen
|
|
1.9 billion yen ($24.2 million as of December 31, 2011)
|
|
1.6 billion yen ($20.2 million as of May 21, 2012)
|
|
3.3%
|
|
Notes due January 2017 with annual principal payments that began in January 2011.
|
|
|
|
|
|
|
|
|
|
|
|
2010 committed loan:
|
|
|
|
|
|
|
|
|
|
|
U.S. dollar
denominated:
|
|
$30.0 million
|
|
$24.0 million
|
|
$22.0 million
|
|
Variable 30 day: 1.24%
|
|
Amortizes at $1.5 million per quarter.
|
|
|
|
|
|
|
|
|
|
|
|
2004 $25.0 million revolving credit facility
|
|
N/A
|
|
None
|
|
None
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009 $100.0 million uncommitted multi-currency shelf facility*
NSJ Operating overdraft loan
|
|
N/A
N/A
|
|
None
None
|
|
None
400 million yen
($5.1 million as of May 21, 2012)
|
|
N/A
Variable
|
|
To be paid in full by May 31, 2012
|
Date
|
Amount of
Loan
|
Maturity Date
|
Amount
Repaid
|
Notation
Made By
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4. | comprised of _______________________ (Type of Loan: Floating Rate Loan, Yen LIBOR Loan or Eurodollar Loan) |
|
|
(i)
|
a consolidated and a consolidating balance sheet of the Company and its Subsidiaries as at the end of such quarter, and
|
(ii)
|
consolidated and consolidating statements of income, changes in shareholders' equity and cash flows of the Company and its Subsidiaries, for such quarter and (in the case of the second and third quarters) for the portion of the fiscal year ending with such quarter,
|
(i)
|
with respect to any Plan, any reportable event, as defined in section 4043(c) of ERISA and the regulations thereunder, for which notice thereof has not been waived pursuant to such regulations as in effect on the date hereof, which could reasonably be expected to have a Material Adverse Effect; or
|
(ii)
|
the taking by the PBGC of steps to institute, or the threatening by the PBGC of the institution of, proceedings under section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Plan, or the receipt by the Company or any ERISA Affiliate of a notice from a Multiemployer Plan that such action has been taken by the PBGC with respect to such Multiemployer Plan, which could reasonably be expected to have a Material Adverse Effect; or
|
(iii)
|
any event, transaction or condition that could result in the incurrence of any liability by the Company or any ERISA Affiliate pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate pursuant to Title I or IV of ERISA or such penalty or excise tax provisions, if such liability or Lien, taken together with any other such liabilities or Liens then existing, could reasonably be expected to have a Material Adverse Effect;
|
(i)
|
in the case of a consolidation or merger of a Restricted Subsidiary, (x) the Company or another Restricted Subsidiary is the surviving or continuing corporation, (y) the surviving or continuing corporation is or immediately
|
(ii)
|
becomes a Restricted Subsidiary, or (z) such consolidation or merger, if considered as the sale of the assets of such Restricted Subsidiary to such other Person, would be permitted by Section 10.2(c); and in the case of a consolidation or merger of the Company, the successor corporation or surviving corporation which results from such consolidation or merger (the "surviving corporation"), if not the Company, (A) is a solvent U.S. corporation, (B) executes and delivers to each holder of the Notes its assumption of (x) the due and punctual payment of the principal of and premium, if any, and interest on all of the Notes, and (y) the due and punctual performance and observation of all of the covenants in this Agreement, the Notes and the other Transaction Documents to be performed or observed by the Company, and (C) furnishes to each holder of the Notes an opinion of counsel, reasonably satisfactory to the Required Holders, to the effect that the instrument of assumption has been duly authorized, executed and delivered and constitutes the legal, valid and binding contract and agreement of the surviving corporation enforceable in accordance with its terms, except as enforcement of such terms may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors' rights generally and by general equitable principles.
|
(i)
|
the successor corporation to which all or substantially all of the Company's assets have been sold, leased or transferred (the "successor corporation") is a solvent U.S. corporation, and
|
(ii)
|
the successor corporation executes and delivers to each holder of the Notes its assumption of the due and punctual payment of the principal of and premium, if any, and interest on all of the Notes, and the due and punctual performance and observation of all of the covenants in this Agreement, the Notes and the other Transaction Documents to be performed or observed by the Company and shall furnish to such holders an opinion of counsel, reasonably satisfactory to the Required Holders, to the effect that the instrument of assumption has been duly authorized, executed and delivered and constitutes the legal, valid and binding contract and agreement of such successor corporation enforceable in accordance with its terms, except as enforcement of such terms may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors' rights generally and by general equitable principles.
|
(i)
|
the sale, lease, transfer or other disposition of assets of the Company to a Wholly-Owned Restricted Subsidiary or of a Restricted Subsidiary to the Company or a Wholly-Owned Restricted Subsidiary;
|
(ii)
|
the sale in the ordinary course of business of inventory held for sale, or equipment, fixtures, supplies or materials that are no longer required in the operation of the business of the Company or any Restricted Subsidiary or are obsolete;
|
(iii)
|
the sale of property of the Company or any Restricted Subsidiary and the Company's or any Restricted Subsidiary's subsequent lease, as lessee, of the same property, within 270 days following the acquisition or construction of such property;
|
(iv)
|
the sale of assets of the Company or any Restricted Subsidiary for cash or other property to a Person or Persons (other than an Affiliate) if (A) such assets (valued at net book value) do not constitute a "substantial part" of the assets of the Company and the Restricted Subsidiaries, (B) in the opinion of a Responsible Officer of the Company, the sale is for fair value and is in the best interests of the Company, and (C) immediately after giving effect to the transaction, no Default or Event of Default would exist; or
|
(v)
|
the sale of assets meeting the conditions set forth in clauses (B) and (C) of subparagraph (iv) above, as long as the net proceeds from such sale in excess of a substantial part of the assets of the Company and the Restricted Subsidiaries are (x) applied within 270 days of the date of receipt to the acquisition of productive assets useful and intended to be used in the operation of the business of the Company or the Restricted Subsidiaries, or (y) used to repay any Indebtedness of the Company (which in the case of the Notes shall be with the Make-Whole Amount) or the Restricted Subsidiaries (other than Indebtedness that is in any manner subordinated in right of payment or security in any respect to Indebtedness evidenced by the Notes, Indebtedness owing to the Company, any of its Subsidiaries or any Affiliate and Indebtedness in respect of any revolving credit or similar credit facility providing the Company or any of the Restricted Subsidiaries with the right to obtain loans or other extensions of credit from time to time, except to the extent that in connection with such payment of Indebtedness the availability of credit under such credit facility is permanently reduced not later than 270 days after the date of receipt of such proceeds by an amount not less than the amount of such proceeds applied to the payment of such Indebtedness).
|
16.
|
SURVIVAL OF REPRESENTATIONS AND WARRANTIES; ENTIRE AGREEMENT.
|
(i)
|
without the written consent of the holders of all Notes of a particular Series, and if an Event of Default shall have occurred and be continuing, of the holders of all Notes of all Series, at the time outstanding, the Notes of such Series may not be amended or the provisions thereof waived to change the maturity thereof, to change or affect the principal thereof, or to change or affect the rate or time of payment of interest on or any Make-Whole Amount payable with respect to the Notes of such Series,
|
(ii)
|
without the written consent of the holder or holders of all Notes at the time outstanding, no amendment to or waiver of the provisions of this Agreement shall change or affect the provisions of Section 12 or this Section 17 insofar as such provisions relate to proportions of the principal amount of the Notes of any Series, or the rights of any individual holder of Notes, required with respect to any declaration of Notes to be due and payable or with respect to any consent, amendment, waiver or declaration,
|
(iii)
|
without the written consent of Prudential, the provisions of Section 2B may not be amended or waived (provided that if any such amendment or waiver would affect any rights or obligations with respect to the purchase and sale of Notes which shall have become Accepted Notes prior to such amendment or waiver, the requirements of clause (iv), below, must also be satisfied), and
|
(iv)
|
without the written consent of all of the Purchasers which shall have become obligated to purchase Accepted Notes of any Series, no provision of Sections 2B or 3 may be amended or waived if such amendment or waiver would affect the rights or obligations with respect to the purchase and sale of the Accepted Notes of such Series or the terms and provisions of such Accepted Notes.
|
Name in Which Notes are to be Registered
|
THE PRUDENTIAL INSURANCE COMPANY OF AMERICA
|
Note Registration Numbers;
Original Principal Amounts
|
C-1 ¥ 1,985,464,000 (Japanese Yen)
D-1 $12,750,000
D-2 $20,000,000
E-2 $7,300,000
E-8 $3,267,648
EE-1 ¥ 2,170,000,000 (Japanese Yen)
F-1 ¥ 1,300,698,000 (Japanese Yen)
|
Payment on Account of Notes -
Dollar Denominated Notes |
Payments shall be made by wire transfer of immediately available funds for credit to:
JPMorgan Chase Bank New York, NY ABA No.: In the case of payments on account of Notes D-1 and E-6:
Account Name: Account No.: In the case of payments on account of Note D-2 and E-2: Account Name: Account No.: Re: (See "Accompanying information" below)
|
Payment on Account of Notes -
Japanese Yen Denominated Notes |
Payments shall be made by wire transfer of immediately available funds for credit to:
JP Morgan Chase Bank, Tokyo
Account Name:
Account No.:
Swift:
FFC:
IBAN #:
Re: (See "Accompanying information" below)
|
Accompanying Information
|
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 1.7225% Series C Senior Notes due April 30, 2014
PPN:
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.19% Series D Senior Notes due July 5, 2016
PPN:
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.14% Series E Senior Notes due January 20, 2017
PPN:
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 3.275% Series EE Senior Notes due January 20, 2017
PPN:
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 2.59% Series F Senior Notes due September 28, 2017
PPN:
Each such wire transfer shall also set forth the due date and application (as among principal, interest and Make-Whole Amount) of the payment being made.
|
Address for Notices Related to Payments
|
The Prudential Insurance Company of America
c/o Investment Operations Group
Gateway Center Two, 10th Floor
100 Mulberry Street
Newark, NJ 07102-4077
Attn: Manager, Billings and Collections
with telephonic prepayment notices to:
Manager, Trade Management Group
Tel:
Fax:
|
Address for All Other Notices
|
The Prudential Insurance Company of America
c/o Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, California 94111-4180
Attn: Managing Director
Fax:
|
Other Instructions
|
THE PRUDENTIAL INSURANCE COMPANY OF AMERICA
By: ________________________________
Name:
Title: Vice President
|
Instructions re Delivery of Notes
|
Send physical security by nationwide overnight delivery service to:
Prudential Capital Group Four Embarcadero Center, Suite 2700
San Francisco, CA 94111-4180
Attn:
Telephone: |
Tax Identification Number
|
|
Name in Which Notes are to be Registered
|
PRUDENTIAL RETIREMENT INSURANCE AND ANNUITY COMPANY
|
Note Registration Numbers;
Original Principal Amounts
|
C-2 ¥ 1,134,536,000 (Japanese Yen)
D-4 $3,000,000
E-4 $1,100,000
F-2¥ 967,302,000 (Japanese Yen) |
Payment on Account of Notes -
Dollar Denominated Notes |
Payments shall be made by wire transfer of immediately available funds for credit to:
JPMorgan Chase Bank
New York, NY
ABA No.:
Account Name:
Account No.:
Re: (See "Accompanying information" below)
|
Payment on Account of Notes -
Japanese Yen Denominated Notes |
Payments shall be made by wire transfer of immediately available funds for credit to:
JP Morgan Chase Bank, Tokyo
Account Name:
Account No.:
Swift:
FFC:
IBAN #:
Re: (See "Accompanying information" below)
|
Accompanying Information
|
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 1.7225% Series C Senior Notes due April 30, 2014
PPN:
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.19% Series D Senior Notes due July 5, 2016
PPN:
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.14% Series E Senior Notes due January 20, 2017
PPN:
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 2.59% Series F Senior Notes due September 28, 2017
PPN:
Each such wire transfer shall also set forth the due date and application (as among principal, interest and Make-Whole Amount) of the payment being made.
|
Address for Notices Related to Payments
|
Prudential Retirement Insurance and Annuity Company
c/o Prudential Investment Management, Inc.
Private Placement Trade Management
PRIAC Administration
Gateway Center Four, 7th Floor
100 Mulberry Street
Newark, NJ 07102
with telephonic prepayment notices to:
Manager, Trade Management Group
Tel:
Fax:
|
Address for All Other Notices
|
Prudential Retirement Insurance and Annuity Company
c/o Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, California 94111-4180
Attn: Managing Director
Fax:
|
Other Instructions
|
PRUDENTIAL RETIREMENT INSURANCE AND ANNUITY COMPANY
By: Prudential Investment Management, Inc., investment manager
By: ________________________________
Name:
Title: Vice President
|
Instructions re Delivery of Notes
|
Send physical security by nationwide overnight delivery service to:
Prudential Capital Group Four Embarcadero Center, Suite 2700
San Francisco, CA 94111-4180
Attn:
Telephone: |
Tax Identification Number
|
|
Name in Which Notes are to be Registered
|
PRUCO LIFE INSURANCE COMPANY OF NEW JERSEY
|
Note Registration Numbers;
Original Principal Amounts
|
D-3 $4,250,000
|
Payment on Account of Notes
|
Payments shall be made by wire transfer of immediately available funds for credit to:
JPMorgan Chase Bank
New York, NY
ABA No.:
Account No.:
Account Name:
Re: (see "Accompanying Information" below)
|
Accompanying Information
|
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.19% Series D Senior Notes due July 5, 2016
PPN:
Each such wire transfer shall also set forth the due date and application (as among principal, interest, and Make-Whole Amount) of the payment being made.
|
Address for Notices Related to Payments
|
Pruco Life Insurance Company of New Jersey
c/o The Prudential Insurance Company of America
c/o Investment Operations Group
Gateway Center Two, 10th Floor
100 Mulberry Street
Newark, NJ 07102-4077
Attn: Manager, Billings and Collections
with telephonic prepayment notices to:
Manager, Trade Management Group
Tel:
Fax:
|
Address for All Other Notices
|
Pruco Life Insurance Company of New Jersey
c/o Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, California 94111-4180
Attn: Managing Director
Fax:
|
Other Instructions
|
PRUCO LIFE INSURANCE COMPANY OF NEW JERSEY
By: ________________________________
Name:
Title: Vice President
|
Instructions re Delivery of Notes
|
Send physical security by nationwide overnight delivery service to:
Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, CA 94111-4180
Attn:
Telephone: |
Tax Identification Number
|
|
Name in Which Notes are to be Registered
|
PRUCO LIFE INSURANCE COMPANY
|
Note Registration Numbers;
Original Principal Amounts
|
E-3 $3,100,000
|
Payment on Account of Notes
|
Payments shall be made by wire transfer of immediately available funds for credit to:
JPMorgan Chase Bank
New York, NY
ABA No.:
Account No.:
Account Name:
Re: (see "Accompanying Information" below)
|
Accompanying Information
|
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.14% Series E Senior Notes due January 20, 2017
PPN:
Each such wire transfer shall also set forth the due date and application (as among principal, interest, and Make-Whole Amount) of the payment being made.
|
Address for Notices Related to Payments
|
Pruco Life Insurance Company
c/o The Prudential Insurance Company of America
c/o Investment Operations Group
Gateway Center Two, 10th Floor
100 Mulberry Street
Newark, NJ 07102-4077
Attn: Manager, Billings and Collections
with telephonic prepayment notices to:
Manager, Trade Management Group
Tel:
Fax: (
|
Address for All Other Notices
|
Pruco Life Insurance Company
c/o Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, California 94111-4180
Attn: Managing Director
Fax:
|
Other Instructions
|
PRUCO LIFE INSURANCE COMPANY
By: ________________________________
Name:
Title: Vice President
|
Instructions re Delivery of Notes
|
Send physical security by nationwide overnight delivery service to:
Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, CA 94111-4180
Attn:
Telephone: |
Tax Identification Number
|
|
Name in Which Notes are to be Registered
|
MTL INSURANCE COMPANY
|
Note Registration Numbers;
Original Principal Amounts
|
E-5 $3,000,000
|
Payment on Account of Notes
|
Payments shall be made by wire transfer of immediately available funds for credit to:
Northern Chgo/Trust
ABA No.:
Credit Wire Account No.:
FFC: Insurance Company - Prudential
Re: (See "Accompanying information" below)
|
Accompanying Information
|
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.14% Series E Senior Notes due January 20, 2017
PPN:
Each such wire transfer shall also set forth the due date and application (as among principal, interest, and Make-Whole Amount) of the payment being made.
|
Address for Notices Related to Payments
and Written Confirmations of such Wire Transfers: |
MTL Insurance Company
1200 Jorie Blvd.
Oak Brook, IL 60522-9060
Attention:
|
Address for All Other Notices
|
Prudential Private Placement Investors, L.P.
c/o Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, California 94111-4180
Attn: Managing Director
Fax:
|
Other Instructions
|
MTL INSURANCE COMPANY
By: Prudential Private Placement Investors, L.P., as investment advisor
By: Prudential Private Placement Investors, Inc., as its general partner
By: ________________________________
Name:
Title: Vice President
|
Instructions re Delivery of Notes
|
(a) Send physical security by nationwide overnight delivery service to:
The Northern Trust Company of New York
Harborside Financial Center 10, Suite 1401
3 Second Street
Northern Acct.
Insurance Company - Prudential
Jersey City, NJ 07311
Attn:
Please include in the cover letter accompanying the Note a reference to the Purchaser's account number (MTL Insurance Company-Prudential; Account Number: )
(b) Send copy by nationwide overnight delivery service to:
Prudential Capital Group
Gateway Center 4
100 Mulberry, 7th Floor
Newark, NJ 07102
Attention: Trade Management, Manager
Telephone:
|
Tax Identification Number
|
|
Name in Which Notes are to be Registered
|
THE GIBRALTAR LIFE INSURANCE CO., LTD.
|
Note Registration Numbers;
Original Principal Amounts
|
E-9 $2,232,352
|
All principal, interest and Make-Whole Amount payments on account of Notes
|
Payments shall be made by wire transfer of immediately available funds for credit to:
JPMorgan Chase Bank New York, NY ABA No.: Account Name: Account No.: Re: (See "Accompanying information" below)
|
All payments, other than principal, interest or Make-Whole Amount, on account of Notes
|
Payments shall be made by wire transfer of immediately available funds for credit to:
JPMorgan Chase Bank New York, NY
ABA No.
Account No.
Account Name:
Re: (See "Accompanying information" below)
|
Accompanying Information
|
Name of Company: Nu Skin Enterprises, Inc.
Description of Security: 6.14% Series E Senior Notes due January 20, 2017
PPN:
Each such wire transfer shall also set forth the due date and application (e.g., as among principal, interest and Make-Whole Amount, or type of fee, as applicable) of the payment being made.
|
Address for Notices Related to Payments
|
The Gibraltar Life Insurance Co., Ltd.
2-13-10, Nagata-cho
Chiyoda-ku, Tokyo 100-8953, Japan
Telephone:
Facsimile:
E-mail:
Attention:
|
Address for All Other Notices
|
Prudential Private Placement Investors, L.P.
c/o Prudential Capital Group
Four Embarcadero Center, Suite 2700
San Francisco, California 94111-4180
Attn: Managing Director
Fax:
|
Other Instructions
|
GIBRALTAR LIFE INSURANCE CO., LTD.
By: Prudential Investment Management (Japan), as Investment Manager
By: Prudential Investment Management, Inc., as Sub-Adviser
By:____________________________
Name: Title:Vice President |
Instructions re Delivery of Notes
|
Send physical security by nationwide overnight delivery service to:
Prudential Capital Group Four Embarcadero Center, Suite 2700
San Francisco, CA 94111-4180
Attn:
Telephone: |
Tax Identification Number
|
|
Principal Amount |
Final Maturity Date |
Principal
Prepayment Dates and Amounts |
Interest Payment Period5 |
Name, Address and Wiring
Instructions of Bank |
Number of Account |
I.
|
Accepted Notes: Aggregate principal
amount ________________________ |
DATED:
|
NU SKIN ENTERPRISES, INC.
By:
Its:
|
|
[PRUDENTIAL INVESTMENT MANAGEMENT, INC.]
By:
Vice President
|
|
[PRUDENTIAL AFFILIATE]
By:
Vice President
|
Re: | Release of Liens and Guarantors; Termination of Collateral Documents and Guarantees |
To the Company:
|
Nu Skin Enterprises, Inc.
75 West Center Street
Provo, Utah 84601
Attn: General Counsel
|
To the Executive:
|
At the Executive's last residence as provided by the Executive to the Company for payroll records.
|
|
NU SKIN ENTERPRISES, INC.
|
|
/s/ D. Matthew Dorny
|
|
D. Matthew Dorny
|
|
Vice President and General Counsel
|
|
EXECUTIVE
|
|
/s/ M. Truman Hunt
|
|
M. Truman Hunt
|
1.
|
Confidential Information: Employee acknowledges that during the term of employment with Company he / she may develop, learn and be exposed to information about Company and its business, including but not limited to formulas, business plans, financial data, vendor lists, product and marketing plans, distributor lists and training in Company's manner of doing business in both product categories and direct selling and multi-level marketing strategies, and other trade secrets which information is secret, confidential and vital to the continued success of Company ("Confidential Information"). Employee agrees that he / she will not at any Time (whether during employment or after termination of employment with Company), without the express written consent of Company, disclose, copy, retain, remove from Company's premises or make any use of such Confidential Information except as may be required in the course of his / her employment with Company.
|
2.
|
Conflict of Interest: During employment with Company, Employee shall not have any personal interest that is incompatible with the loyalty and responsibility owed to Company. Employee must discharge his / her responsibility solely on the basis of what is in the best interest of Company and independent of personal considerations or relationships. Although it is difficult to identify every activity that might give rise to a conflict of interest, and not by way of making an all inclusive list, some of the more common circumstances and practices that might result in such conflicts are set forth below. Should Employee have any questions regarding this matter, Employee should consult with and receive written permission from his / her director or supervisor.
|
a.
|
Employee shall maintain impartial relationships with vendors, suppliers and distributors.
|
b.
|
Employee shall not have a direct or indirect ownership interest in vendors of Company nor any company doing or seeking to do business with Company.
|
c.
|
Employee shall not have a direct or indirect ownership in any company which competes with Company in any product category or any direct selling or multi-level marketing company, unless such company's securities are publicly traded on either the NYSE, American or NASDAQ stock exchanges and the Employee's ownership interest is less than 1% of the total outstanding securities of such company.
|
d.
|
Employee shall not perform services of any kind for any entity doing or seeking to do business with Company. As to employment with or service to another company, Employee shall not allow any such activity to detract from his / her job performance, use Company's time, resources, or personnel, or require such long hours to affect his / her physical or mental effectiveness.
|
e.
|
While employed and for a period of three (3) months after termination of an employment relationship with Company, Employee shall not directly or indirectly own any interest in a Company distributorship. Additionally, during the course of employment, neither the Employee, nor the Employee's spouse or an immediate family member living in the same household shall own any interest in a Company distributorship or any other multi-level distributorship. Employee's spouse or immediate family member living in the same household will not, without the prior written consent of the Company, own any interest in another direct sales distributorship or be employed by another direct sales or multi-level marketing company. Any pre-existing ownership interests or employment covered in this paragraph must be disclosed to the Company at the time of the execution of this Agreement.
|
f.
|
Employee shall disclose to his/her immediate director or supervisor any and all areas posing a potential or actual conflict of interest. Said disclosure shall be made as promptly as possible after such conflict arises.
|
3.
|
Work Product: Company shall have the sole proprietary interest in the work product of Employee during his / her employment with Company ("Work Product"), and Employee expressly assigns to Company or its designee all rights, title and interest in and to all copyrights, patents, trade secrets, improvements, inventions, sketches, models and all documents related thereto, manufacturing processes and innovations, special calibration techniques, software, service code, systems designs and any other Work Product developed by Employee, either solely or jointly with others, where said Work Product relates to any business activity or research and development activity in which Company is involved or plans to be involved at the time of or prior to Employee's creating such Work Product, or where such Work Product is developed with the use of Company's time, material, or facilities; and Employee further agrees to disclose any and all such Work Product to Company without delay.
|
4.
|
Ethical Standards: Employee agrees to maintain the highest ethical and legal standards in his / her conduct, to be scrupulously honest and straight-forward in all of his / her dealings and to avoid all situations which might project the appearance of being unethical or illegal.
|
5.
|
Product Resale: As an employee of Company, Employee may receive Company products and materials either at no charge or at a discount as specified from time to time by Company in its sole discretion. Employee agrees that the products received from Company are strictly limited to Employee's personal use and that of Employee's immediate family and may not be resold, given or disposed of to any other person or entity in a manner inconsistent with the personal use herein described.
|
6.
|
Gratuities: Employee shall neither seek nor retain gifts, gratuities, entertainment or other forms of compensation, benefit, or persuasion from suppliers, distributors, vendors or their representatives without the consent of a Company Vice President with the exception of meals provided in the ordinary course of business on an infrequent basis.
|
7.
|
Non-Solicitation: Employee shall not in any way, directly or indirectly, at any time during employment or within two (2) years after either a voluntary or involuntary employment termination: (a) solicit, divert, or take away Company's distributors; (b) solicit in any manner Company's employees, or vendors; or (c) assist any other person in any manner or persons in an attempt to do any of the foregoing.
|
8.
|
Non-Disparagement: Employee shall not in any way, directly or indirectly at any time during employment or after either voluntary or involuntary employment termination, commercially disparage Company, Company products or Company Distributors.
|
9.
|
Non-Endorsement: Employee shall not in any way, directly or indirectly, at any time during employment or within one (1) year after either a voluntary or involuntary employment termination endorse any product that competes with products of Company, promote or speak on behalf of any company whose products compete with those of Company, allow Employee's name or likeness to be used in any way to promote any company or product that competes with Company or any products of Company.
|
10.
|
Non-Competition: In exchange for the benefits of continued employment by Company, Employee shall not accept employment with, engage in or participate, directly or indirectly, individually or as an officer, director, employee, shareholder, consultant, partner, joint venturer, agent, equity owner, distributor or in any other capacity whatsoever, with any direct sales or multi-level marketing company including any direct or indirect affiliate or subsidiary of such company that competes with the business of Company whether for market share of products or for independent distributors in a territory in which Company is doing business. The restrictions set forth in this paragraph shall remain in effect during the Employee's employment with Company and during a period of six months following the Employee's termination of employment. Within fifteen days of termination of Employee's employment, Company shall notify Employee whether it elects to enforce Employee's obligation set forth in this paragraph. In the event Company decides to enforce employees non-competition obligation set forth herein, Company shall pay Employee a sum equal to seventy-five percent of the Employee's base salary at termination of employment, less applicable withholding taxes and excluding all incentive compensation and other benefit payments, for the period following the termination of employment during which the restrictive covenants in this paragraph remain in effect. Payment may be made in periodic installments in accordance with Company's regular payroll practices.
|
11.
|
Acknowledgement: Employee acknowledges that his / her position and work activities with Company are "key" and vital to the on-going success of Company's operation in each product category and in each geographic location in which Company operates. In addition, Employee acknowledges that his / her employment or involvement with any other direct selling or multi-level marketing company in particular would create the impression that Employee has left Company for a "better opportunity," which could damage Company by this perception in the minds of Company's employees or independent distributors. Therefore, Employee acknowledges that his / her confidentiality, non-solicitation, non-disparagement, non-endorsement, and non-competition covenants hereunder are fair and reasonable and should be construed to apply to the fullest extent possible by applicable laws. Employee has carefully read this Agreement, has consulted with independent legal counsel to the extent Employee deems appropriate, and has given careful consideration to the restraints imposed by the Agreement. Employee acknowledges that the terms of this Agreement are enforceable regardless of the manner in which Employee's employment is terminated, whether voluntary or involuntary. In the event that Employee is to be employed as an attorney for a competitive business, Company and Employee acknowledge that paragraph 10 is not intended to restrict the right of the Employee to practice law in violation of any applicable rules of professional conduct.
|
12.
|
Terminations: Upon termination of employment, Employee shall return to Company all assets and equipment of Company along with any Confidential Information and Work Product including any distributor and vendor contact information and notes or summaries of all of the above.
|
13.
|
Remedies: The Employee acknowledges: (a) that compliance with the restrictive covenants contained in this Agreement are necessary to protect the business and goodwill of Company and (b) that a breach will result in irreparable and continuing damage to Company, for which money damages may not provide adequate relief. Consequently, Employee agrees that, in the event that he/she breaches or threatens to breach these restrictive covenants, Company shall be entitled to both: (1) a preliminary or permanent injunction to prevent the continuation of harm and (2) money damages insofar as they can be determined. Nothing in this Agreement shall be construed to prohibit Company from also pursuing any other remedy, the parties having agreed that all remedies are cumulative. It is further recognized and agreed that the covenants set forth herein are for the purpose of restricting Employee's activities to the extent necessary for the protection of the legitimate business interests of Company and that Employee agrees that said covenants do not and will not preclude him / her from engaging in activities sufficient for the purposes of earning a living.
|
14.
|
Attorney's Fees: If any party to this Agreement breaches any of the terms of this Agreement, then that party shall pay to the non-defaulting party all of the non-defaulting party's costs and expenses, including reasonable attorney's fees, incurred by that party in enforcing the terms of this Agreement.
|
15.
|
Court's Right to Modify Restriction: The parties have attempted to limit Employee's right to compete only to the extent necessary to protect Company from unfair competition. The parties recognize, however, that reasonable people may differ in making such a determination. Consequently, the parties agree that, if the scope or enforceability of the restrictive covenants contained in this Agreement are in any way disputed at any time, a court or other trier of fact may modify and enforce the covenants to the extent that it believes to be reasonable under the circumstances existing at that time.
|
16.
|
Severability: If any provision, paragraph, or subparagraph of this Agreement is adjudged by any court or administrative agency to be void or unenforceable in whole or in part, this adjudication shall not affect the validity of the remainder of the Agreement, including any other provision, paragraph, or subparagraph. Each provision, paragraph, and subparagraph of this Agreement is severable from every other provision, paragraph, and subparagraph and constitutes a separate and distinct covenant.
|
17.
|
Governing Law and Forum: This Agreement shall be governed and enforced in accordance with the laws of the State of Utah, and any litigation between the parties relating to this Agreement shall be conducted in the courts of Utah County or Salt Lake City where necessary for federal court matters.
|
18.
|
Employment at Will: Employee understands that employment with Company is at will, meaning that employment with Company is completely voluntary and for an indefinite term and that either Employee or Company is free to terminate the employment relationship at any time, with or without cause or advance notice, provided that termination is not done for an unlawful or discriminatory purpose.
|
19.
|
Entire Agreement: Company and Employee understand and agree that this Agreement shall constitute the entire agreement between them regarding the subject matter contained herein, and that all prior understandings or agreements regarding these matters are hereby superseded and replaced, including, without limitation, the Key-Employee Covenants Agreement previously signed by the parties. Any amendment to or modification of this Agreement must be in writing signed by the parties hereto and stating the intent of the parties to amend or modify this Agreement.
|
1.
|
Executive's total fiscal year target bonus is $1,000,000.
|
(a) | $125,000 (12.5%) is allocated to each quarter and is earned based on that quarter's performance. |
(b) | $500,000 (50%) is allocated to the fiscal year and is earned based on fiscal year performance. |
2.
|
Executive's employment is terminated on 5/15/12.
|
3.
|
Based on actual performance, second quarter bonus was 125% of target bonus and annual bonus was 150% of target bonus.
|
1.
|
Second quarter:
|
2.
|
Fiscal year:
|
3.
|
Total Pro-Rata Earned Bonus: $77,266 + $278,700 = $355,966
|
1.
|
Executive's total fiscal year target bonus is $1,000,000.
|
(a) | $125,000 (12.5%) is allocated to each quarter and is earned based on that quarter's performance. |
2.
|
Executive's employment is terminated on 7/31/12.
|
1.
|
Third quarter:
|
2.
|
Fiscal year:
|
3.
|
Total Pro-Rata Target Bonus: $42,125 + 291,000 = $333,125
|
To the Company:
|
Nu Skin Enterprises, Inc.
75 West Center Street
Provo, Utah 84601
Attn: General Counsel
|
To the Executive:
|
At the Executive's last residence as provided by the Executive to the Company for payroll records.
|
|
NU SKIN ENTERPRISES, INC.
|
|
|
|
M. Truman Hunt
|
|
President and Chief Executive Officer
|
|
EXECUTIVE
|
|
|
|
[NAME]
|
1.
|
Confidential Information: Employee acknowledges that during the term of employment with Company he / she may develop, learn and be exposed to information about Company and its business, including but not limited to formulas, business plans, financial data, vendor lists, product and marketing plans, distributor lists and training in Company's manner of doing business in both product categories and direct selling and multi-level marketing strategies, and other trade secrets which information is secret, confidential and vital to the continued success of Company ("Confidential Information"). Employee agrees that he / she will not at any Time (whether during employment or after termination of employment with Company), without the express written consent of Company, disclose, copy, retain, remove from Company's premises or make any use of such Confidential Information except as may be required in the course of his / her employment with Company.
|
2.
|
Conflict of Interest: During employment with Company, Employee shall not have any personal interest that is incompatible with the loyalty and responsibility owed to Company. Employee must discharge his / her responsibility solely on the basis of what is in the best interest of Company and independent of personal considerations or relationships. Although it is difficult to identify every activity that might give rise to a conflict of interest, and not by way of making an all inclusive list, some of the more common circumstances and practices that might result in such conflicts are set forth below. Should Employee have any questions regarding this matter, Employee should consult with and receive written permission from his / her director or supervisor.
|
a.
|
Employee shall maintain impartial relationships with vendors, suppliers and distributors.
|
b.
|
Employee shall not have a direct or indirect ownership interest in vendors of Company nor any company doing or seeking to do business with Company.
|
c.
|
Employee shall not have a direct or indirect ownership in any company which competes with Company in any product category or any direct selling or multi-level marketing company, unless such company's securities are publicly traded on either the NYSE, American or NASDAQ stock exchanges and the Employee's ownership interest is less than 1% of the total outstanding securities of such company.
|
d.
|
Employee shall not perform services of any kind for any entity doing or seeking to do business with Company. As to employment with or service to another company, Employee shall not allow any such activity to detract from his / her job performance, use Company's time, resources, or personnel, or require such long hours to affect his / her physical or mental effectiveness.
|
e.
|
While employed and for a period of three (3) months after termination of an employment relationship with Company, Employee shall not directly or indirectly own any interest in a Company distributorship. Additionally, during the course of employment, neither the Employee, nor the Employee's spouse or an immediate family member living in the same household shall own any interest in a Company distributorship or any other multi-level distributorship. Employee's spouse or immediate family member living in the same household will not, without the prior written consent of the Company, own any interest in another direct sales distributorship or be employed by another direct sales or multi-level marketing company. Any pre-existing ownership interests or employment covered in this paragraph must be disclosed to the Company at the time of the execution of this Agreement.
|
f.
|
Employee shall disclose to his/her immediate director or supervisor any and all areas posing a potential or actual conflict of interest. Said disclosure shall be made as promptly as possible after such conflict arises.
|
3.
|
Work Product: Company shall have the sole proprietary interest in the work product of Employee during his / her employment with Company ("Work Product"), and Employee expressly assigns to Company or its designee all rights, title and interest in and to all copyrights, patents, trade secrets, improvements, inventions, sketches, models and all documents related thereto, manufacturing processes and innovations, special calibration techniques, software, service code, systems designs and any other Work Product developed by Employee, either solely or jointly with others, where said Work Product relates to any business activity or research and development activity in which Company is involved or plans to be involved at the time of or prior to Employee's creating such Work Product, or where such Work Product is developed with the use of Company's time, material, or facilities; and Employee further agrees to disclose any and all such Work Product to Company without delay.
|
4.
|
Ethical Standards: Employee agrees to maintain the highest ethical and legal standards in his / her conduct, to be scrupulously honest and straight-forward in all of his / her dealings and to avoid all situations which might project the appearance of being unethical or illegal.
|
5.
|
Product Resale: As an employee of Company, Employee may receive Company products and materials either at no charge or at a discount as specified from time to time by Company in its sole discretion. Employee agrees that the products received from Company are strictly limited to Employee's personal use and that of Employee's immediate family and may not be resold, given or disposed of to any other person or entity in a manner inconsistent with the personal use herein described.
|
6.
|
Gratuities: Employee shall neither seek nor retain gifts, gratuities, entertainment or other forms of compensation, benefit, or persuasion from suppliers, distributors, vendors or their representatives without the consent of a Company Vice President with the exception of meals provided in the ordinary course of business on an infrequent basis.
|
7.
|
Non-Solicitation: Employee shall not in any way, directly or indirectly, at any time during employment or within two (2) years after either a voluntary or involuntary employment termination: (a) solicit, divert, or take away Company's distributors; (b) solicit in any manner Company's employees, or vendors; or (c) assist any other person in any manner or persons in an attempt to do any of the foregoing.
|
8.
|
Non-Disparagement: Employee shall not in any way, directly or indirectly at any time during employment or after either voluntary or involuntary employment termination, commercially disparage Company, Company products or Company Distributors.
|
9.
|
Non-Endorsement: Employee shall not in any way, directly or indirectly, at any time during employment or within one (1) year after either a voluntary or involuntary employment termination endorse any product that competes with products of Company, promote or speak on behalf of any company whose products compete with those of Company, allow Employee's name or likeness to be used in any way to promote any company or product that competes with Company or any products of Company.
|
10.
|
Non-Competition: In exchange for the benefits of continued employment by Company, Employee shall not accept employment with, engage in or participate, directly or indirectly, individually or as an officer, director, employee, shareholder, consultant, partner, joint venturer, agent, equity owner, distributor or in any other capacity whatsoever, with any direct sales or multi-level marketing company including any direct or indirect affiliate or subsidiary of such company that competes with the business of Company whether for market share of products or for independent distributors in a territory in which Company is doing business. The restrictions set forth in this paragraph shall remain in effect during the Employee's employment with Company and during a period of six months following the Employee's termination of employment. Within fifteen days of termination of Employee's employment, Company shall notify Employee whether it elects to enforce Employee's obligation set forth in this paragraph. In the event Company decides to enforce employees non-competition obligation set forth herein, Company shall pay Employee a sum equal to seventy-five percent of the Employee's base salary at termination of employment, less applicable withholding taxes and excluding all incentive compensation and other benefit payments, for the period following the termination of employment during which the restrictive covenants in this paragraph remain in effect. Payment may be made in periodic installments in accordance with Company's regular payroll practices.
|
11.
|
Acknowledgement: Employee acknowledges that his / her position and work activities with Company are "key" and vital to the on-going success of Company's operation in each product category and in each geographic location in which Company operates. In addition, Employee acknowledges that his / her employment or involvement with any other direct selling or multi-level marketing company in particular would create the impression that Employee has left Company for a "better opportunity," which could damage Company by this perception in the minds of Company's employees or independent distributors. Therefore, Employee acknowledges that his / her confidentiality, non-solicitation, non-disparagement, non-endorsement, and non-competition covenants hereunder are fair and reasonable and should be construed to apply to the fullest extent possible by applicable laws. Employee has carefully read this Agreement, has consulted with independent legal counsel to the extent Employee deems appropriate, and has given careful consideration to the restraints imposed by the Agreement. Employee acknowledges that the terms of this Agreement are enforceable regardless of the manner in which Employee's employment is terminated, whether voluntary or involuntary. In the event that Employee is to be employed as an attorney for a competitive business, Company and Employee acknowledge that paragraph 10 is not intended to restrict the right of the Employee to practice law in violation of any applicable rules of professional conduct.
|
12.
|
Terminations: Upon termination of employment, Employee shall return to Company all assets and equipment of Company along with any Confidential Information and Work Product including any distributor and vendor contact information and notes or summaries of all of the above.
|
13.
|
Remedies: The Employee acknowledges: (a) that compliance with the restrictive covenants contained in this Agreement are necessary to protect the business and goodwill of Company and (b) that a breach will result in irreparable and continuing damage to Company, for which money damages may not provide adequate relief. Consequently, Employee agrees that, in the event that he/she breaches or threatens to breach these restrictive covenants, Company shall be entitled to both: (1) a preliminary or permanent injunction to prevent the continuation of harm and (2) money damages insofar as they can be determined. Nothing in this Agreement shall be construed to prohibit Company from also pursuing any other remedy, the parties having agreed that all remedies are cumulative. It is further recognized and agreed that the covenants set forth herein are for the purpose of restricting Employee's activities to the extent necessary for the protection of the legitimate business interests of Company and that Employee agrees that said covenants do not and will not preclude him / her from engaging in activities sufficient for the purposes of earning a living.
|
14.
|
Attorney's Fees: If any party to this Agreement breaches any of the terms of this Agreement, then that party shall pay to the non-defaulting party all of the non-defaulting party's costs and expenses, including reasonable attorney's fees, incurred by that party in enforcing the terms of this Agreement.
|
15.
|
Court's Right to Modify Restriction: The parties have attempted to limit Employee's right to compete only to the extent necessary to protect Company from unfair competition. The parties recognize, however, that reasonable people may differ in making such a determination. Consequently, the parties agree that, if the scope or enforceability of the restrictive covenants contained in this Agreement are in any way disputed at any time, a court or other trier of fact may modify and enforce the covenants to the extent that it believes to be reasonable under the circumstances existing at that time.
|
16.
|
Severability: If any provision, paragraph, or subparagraph of this Agreement is adjudged by any court or administrative agency to be void or unenforceable in whole or in part, this adjudication shall not affect the validity of the remainder of the Agreement, including any other provision, paragraph, or subparagraph. Each provision, paragraph, and subparagraph of this Agreement is severable from every other provision, paragraph, and subparagraph and constitutes a separate and distinct covenant.
|
17.
|
Governing Law and Forum: This Agreement shall be governed and enforced in accordance with the laws of the State of Utah, and any litigation between the parties relating to this Agreement shall be conducted in the courts of Utah County or Salt Lake City where necessary for federal court matters.
|
18.
|
Employment at Will: Employee understands that employment with Company is at will, meaning that employment with Company is completely voluntary and for an indefinite term and that either Employee or Company is free to terminate the employment relationship at any time, with or without cause or advance notice, provided that termination is not done for an unlawful or discriminatory purpose.
|
19.
|
Entire Agreement: Company and Employee understand and agree that this Agreement shall constitute the entire agreement between them regarding the subject matter contained herein, and that all prior understandings or agreements regarding these matters are hereby superseded and replaced, including, without limitation, the Key-Employee Covenants Agreement previously signed by the parties. Any amendment to or modification of this Agreement must be in writing signed by the parties hereto and stating the intent of the parties to amend or modify this Agreement.
|
1.
|
Executive's total fiscal year target bonus is $1,000,000.
|
(a) | $125,000 (12.5%) is allocated to each quarter and is earned based on that quarter's performance. |
(b) | $500,000 (50%) is allocated to the fiscal year and is earned based on fiscal year performance. |
2.
|
Executive's employment is terminated on 5/15/12.
|
3.
|
Based on actual performance, second quarter bonus was 125% of target bonus and annual bonus was 150% of target bonus.
|
1.
|
Second quarter:
|
2.
|
Fiscal year:
|
3.
|
Total Pro-Rata Earned Bonus: $77,266 + $278,700 = $355,966
|
1.
|
Executive's total fiscal year target bonus is $1,000,000.
|
(a) | $125,000 (12.5%) is allocated to each quarter and is earned based on that quarter's performance. |
2.
|
Executive's employment is terminated on 7/31/12.
|
1.
|
Third quarter:
|
2.
|
Fiscal year:
|
NAME
|
TITLE
|
Ritch N. Wood
|
Chief Financial Officer
|
Daniel R. Chard
|
President, Global Sales and Operations
|
Scott E. Schwerdt
|
President, Americas Region
|
D. Matthew Dorny
|
Vice President and General Counsel
|